Feature

Nautilus founder unspirals a new approach to proteomics

Laurel Oldach
Sept. 21, 2021

Parag Mallick’s latest project comes with an interesting challenge. “People keep trying to get me to say bad things about mass spectrometers,” he said in a recent interview. “You’re not going to get me to do it.”

Mallick-Parag-445x578.jpg
Nautilus BIotechnology
Parag Mallick

The goal of Mallick’s company, Nautilus Biotechnology, sounds antithetical to the room-sized, half-million–dollar instruments. He intends to collect comparable data more cheaply using a benchtop instrument, proprietary reagents and an algorithm.

But Mallick, a Stanford University professor and founder and chief scientist of Nautilus, which recently went public, is the consummate mass spectrometry insider. Though his company’s mission is to make proteomics more accessible — their slogan is “Anybody who wants a proteome gets a proteome” — he argues that the expanding field can accommodate both new approaches and established mass spec techniques.

Time will tell whether his generalist attitude can be balanced with a tech company’s disruptive approach.

The technology

Nautilus researchers measure a proteome using a technique Mallick invented in 2016. It depends on repeated single-molecule imaging of a series of antibodies binding proteins fixed to a chip — Mallick compares it to a chessboard with 10 billion tiny squares.

Chip-based approaches to proteomics are not new; protein microarrays, in which proteins bind to antibodies adsorbed to known locations on a chip, have been in use for more than 20 years. The Nautilus approach is special because the protein sample, not the antibody probe, is fixed in place, with single proteins from the sample spaced apart by ligation to much larger polymer particles. More importantly, whereas a microarray is probed once, the proteomes Nautilus measures can be probed again and again using a line of antibodies developed in-house.

“People often do complain about their affinity reagents cross-reacting or not being specific enough,” Mallick said. “That was really the critical realization for us: to say, let’s take that concept to extremes as well, and build a class of reagents that are intentionally highly cross-reactive.”

Nautilus-Biotechnology-integrated-single-molecule-proteome-analysis-890x243.jpg
Nautilus BIotechnology
A promotional schematic from Nautilus shows the benchtop proteomics instrument the company hopes to sell. “Can we call it a Nautilus Shell?” proteomics researcher David Tabb joked.

The team developed hundreds of antibodies that bind to very short epitopes, as little as a few amino acids long, that are found in many proteins. They probe with one, wash it away, and probe with the next, collecting a series of images that shows whether the molecule at each location on the chip binds with antibody 1, antibody 17 or antibody 84.

“Each one of these touches, from each one of these probes, is just a tiny little nugget of information,” Mallick said.

Those nuggets feed a machine-learning algorithm that analyzes terabytes of data per run, about 10 times as much information as is in a whole-genome sequencing run, and matches the characteristics of each spot to proteins in the proteome. The approach is particularly well suited to identifying proteoforms because of its single-molecule resolution. According to Mallick, although each binding event gives just a small amount of information about a protein, as few as 200 or 300 cycles might be enough to identify 95% of the human proteome, including specific proteoforms.

The company

Though Mallick has invented a potentially revolutionary technology and founded a company that’s already attracting big-name venture capitalists, he comes off in interviews as careful, knowledgeable and a little self-effacing. He’s an amateur magician and juggler but hid the hobby for years, concerned that his colleagues might not take him seriously as a researcher if they knew he was performing sleight of hand in his spare time.

Nautilus-Biotechnology-platform-445x256.jpg
Nautilus Biotechnology
An artist’s rendering of Nautilus Biotechnology’s platform shows how individual proteins are adsorbed to a chip and repeatedly probed for short amino acid sequences.

During a recent webinar sponsored by the Human Proteome Organization, Mallick discussed Nautilus with Mark Baker, a former HUPO president and past chair of its human proteome project.

That the technology behind Nautilus would nucleate a company was not a foregone conclusion, Mallick said in the webinar. When he first had what he called “a crazy brainstorm on a weekend,” he explored several options for making it a reality, including licensing the technology to a larger company or developing it within his university lab.

Before Nautilus, he was an academic, and he’s still a professor — albeit on partial leave — at Stanford. He trained in the lab of mass spectrometry and systems biology pioneer Ruedi Aebersold, one of the most prominent researchers in the field. David Tabb, who was a graduate student at the same time in a friendly competitor’s laboratory in Seattle, said that even then, Mallick was more focused on unsolved problems than on incremental process improvements.

Later, as professors, Tabb and Mallick, along with their students Matt Chambers and Darren Kessner, co-developed a software platform called ProteoWizard that could be used to analyze mass spec data no matter what type of instrument it came from. The two labs made the software openly available, and it has been cited almost 1,400 times.

Despite that open-science background, Tabb said, it’s no great surprise that Mallick founded a company. “He’s always been smart,” Tabb said, adding that “Stanford, in general, has done a lot to incubate biotech businesses from its laboratories. … I think he had a good idea and saw a way to pursue it.”

When he was developing the idea for the new technology, Mallick said, he concluded that solving problems in biochemistry, genomics, materials science, microscopy, machine learning and other fields would move fastest in a startup. “It can be a challenge to marshal that scale in academia,” he said. “Even in the largest, most well-funded labs, you usually have a diversity of projects. We literally have every single person contributing to one goal.”

Mallick reached out for advice to contacts in the business community, including Sujal Patel, an entrepreneur and investor. Patel became a cofounder and is now the company’s chief executive officer.

“One of the lessons there is sometimes surprising things come from your network,” Mallick told Mark Baker during the HUPO webinar.

Will everyone get a proteome?

“Mass spectrometry is great for proteomics,” Tabb said. “Is it always going to be the go-to technology for identifying proteins and protein differences? I think 100 years from now, we’ll have very different answers to that question.”

According to Baker, Nautilus is making a fair bid to become one of those future answers. In an email, he wrote, “Assuming Nautilus’ platform can successfully quantify >95% of the human proteome (their vision) with a simple, fast and cheap sample prep and analysis, the concept could become as ubiquitous as sequencing a person’s genome has become today.”

Although he hopes the Nautilus platform will make proteomic experiments much more widely accessible, Mallick said that when it first rolls out, it will cost about the same per run as mass spectrometry.

Tabb, now a professor at Stellenbosch University in South Africa, said that while the Nautilus technology eventually may bring down the cost of acquiring a proteome, it is likely to remain out of reach for many researchers in the developing world. Instead, he said labs in poorer countries likely will have to find wealthier collaborators with access to instruments. That often can mean forfeiting senior authorship in order to get the experiments done. “That’s the way things have unfolded with proteomics,” he said. “That’s the way things have unfolded with sequencing.”

Whatever the cost of using a future system, it will be some time before Nautilus offers a product that any lab could buy. The company now is working exclusively with partners in the pharmaceutical industry, including Genentech, on targeted assays that do not use its custom antibodies.

“It’s very early days for Nautilus — they are only a recent spinout,” Baker wrote, while also noting, “they are moving fast, they have the backing of major tried-and-true successful investors (and) they have launched on NASDAQ.”

In the wake of that launch, the founders of Nautilus plan to double its research team and begin publishing on its approach to protein identification.

Mallick-Patel-890x515.jpg
Nautilus Biotechnology
Parag Mallick and cofounder Sujal Patel.

A previous version of this article misstated Parag Mallick's title at Nautilus. He is the founder and chief scientist. There was also an error in the name of Nautilus's partner company: The correct name is Genentech.

Enjoy reading ASBMB Today?

Become a member to receive the print edition monthly and the digital edition weekly.

Learn more
Laurel Oldach

Laurel Oldach is a science writer for the ASBMB.

Get the latest from ASBMB Today

Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.

Latest in Industry

Industry highlights or most popular articles

‘We're all a bunch of weirdos doing our stuff’
Jobs

‘We're all a bunch of weirdos doing our stuff’

May 20, 2022

An interview with Charles Sanders, a research associate at XBiotech.

How Robert Langer failed repeatedly but kept going
Interview

How Robert Langer failed repeatedly but kept going

May 3, 2022

"They said I should give up, but I don’t like to give up," the pioneer in delivering mRNA to the body said.

'Anywhere you go, be ready to review your work'
Interview

'Anywhere you go, be ready to review your work'

April 29, 2022

Maria Grandoni is a scientist at PPD. She talked to our industry careers columnist about her work on the manufacturing and quality side of industry.

Ole Miss strikes $5M deal with company warned for claiming essential oils can cure COVID
News

Ole Miss strikes $5M deal with company warned for claiming essential oils can cure COVID

April 26, 2022

Companies have long sought to partner on research with public universities, which, starved for state funding, eagerly take private dollars.

‘Have faith in that training’
Interview

‘Have faith in that training’

March 18, 2022

Raghuvir Sengupta has been a biochemist for HP and is now a Pfizer postdoc. He talks about his work and how his graduate training prepared him for his industry career.

90% of drugs fail clinical trials
Editorial

90% of drugs fail clinical trials

March 12, 2022

Here’s one way researchers can select better drug candidates.